BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced the presentation of two abstracts detailing positive preclinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The abstracts and an oral educational session, which were presented at the American Association for Cancer Research (AACR) 100th Annual Meeting, suggest that ARRY-520 may be a promising therapy for the treatment of hematological and taxane-resistant malignancies. ARRY-520 is a highly potent, selective KSP inhibitor currently in a Phase 1 trial for solid tumors and Phase 1/2 trials for multiple myeloma and acute myelogenous leukemia (AML). The complete presentations are available as PDFs on Array's website at www.arraybiopharma.com.
